A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer-Reference-Cited by-同舟云学术

A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer

Published:2023-02-01 Issue:3 Volume:62 Page:327-334
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Okano Naohiro¹,Matsuki Ryota²,Toki Masao³,Gondo Koichi³,Ochiai Kazushige³,Watanabe Shunsuke³,Tateishi Hidekatsu⁴,Kogure Masaharu²,Suzuki Yutaka²,Sugiyama Masanori⁵,Nagashima Fumio¹,Shibahara Junji⁶,Sakamoto Yoshihiro²,Furuse Junji¹

Affiliation:

1. Department of Medical Oncology, Kyorin University Faculty of Medicine, Japan

2. Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, Japan

3. Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Japan

4. Department of Radiology, Kyorin University Faculty of Medicine, Japan

5. Tokyo Rosai Hospital, Japan

6. Department of Pathology, Kyorin University Faculty of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9504-22/_pdf

Reference36 articles.

1. 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 71: 7-33, 2021.

2. 2. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2.2021 [Internet]. [cited 2021 Dec 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

3. 3. Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 68: 130-139, 2019.

4. 4. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007.

5. 5. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389: 1011-1024, 2017.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancreatic cancer;Pancreatology;2023-12

2. Gemcitabine/paclitaxel;Reactions Weekly;2023-04-15